Robeco Institutional Asset Management B.V. Buys 168,153 Shares of Stryker Corporation (NYSE:SYK)

Robeco Institutional Asset Management B.V. boosted its stake in Stryker Corporation (NYSE:SYK) by 109.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 321,247 shares of the medical technology company’s stock after buying an additional 168,153 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Stryker were worth $119,584,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Kohmann Bosshard Financial Services LLC purchased a new stake in Stryker in the 4th quarter valued at about $25,000. Capital A Wealth Management LLC bought a new stake in Stryker during the fourth quarter worth $26,000. Rakuten Securities Inc. increased its position in shares of Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after purchasing an additional 68 shares during the last quarter. City Holding Co. grew its position in Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock valued at $33,000 after buying an additional 74 shares during the period. Finally, BankPlus Trust Department bought a new position in Stryker during the fourth quarter valued at $33,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

NYSE:SYK opened at $392.36 on Thursday. Stryker Corporation has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.64 and a quick ratio of 1.00. The business has a 50 day moving average of $377.18 and a 200 day moving average of $375.31. The company has a market capitalization of $149.76 billion, a price-to-earnings ratio of 53.02, a PEG ratio of 2.91 and a beta of 0.91.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts’ consensus estimates of $2.73 by $0.11. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The firm had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. During the same period in the previous year, the business posted $2.50 EPS. The business’s quarterly revenue was up 11.9% on a year-over-year basis. On average, sell-side analysts predict that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker’s dividend payout ratio is presently 45.41%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Citigroup reiterated a “buy” rating and set a $455.00 price target (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. BTIG Research set a $403.00 target price on shares of Stryker and gave the stock a “buy” rating in a report on Monday, April 14th. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, June 14th. Needham & Company LLC restated a “buy” rating and set a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. Finally, Roth Mkm increased their price objective on Stryker from $405.00 to $456.00 and gave the stock a “buy” rating in a research report on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $427.30.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.